These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 22957857

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The therapeutic potential of 5-HT1A receptors: a patent review.
    Lacivita E, Di Pilato P, De Giorgio P, Colabufo NA, Berardi F, Perrone R, Leopoldo M.
    Expert Opin Ther Pat; 2012 Aug; 22(8):887-902. PubMed ID: 22788968
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S.
    J Med Chem; 2003 Feb 27; 46(5):702-15. PubMed ID: 12593651
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor.
    Kim Y, Kim J, Tae J, Roth BL, Rhim H, Keum G, Nam G, Choo H.
    Bioorg Med Chem; 2013 May 01; 21(9):2568-76. PubMed ID: 23541835
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic Potential of 5-HT6 Receptor Agonists.
    Karila D, Freret T, Bouet V, Boulouard M, Dallemagne P, Rochais C.
    J Med Chem; 2015 Oct 22; 58(20):7901-12. PubMed ID: 26099069
    [Abstract] [Full Text] [Related]

  • 12. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
    van Loevezijn A, Venhorst J, Iwema Bakker WI, de Korte CG, de Looff W, Verhoog S, van Wees JW, van Hoeve M, van de Woestijne RP, van der Neut MA, Borst AJ, van Dongen MJ, de Bruin NM, Keizer HG, Kruse CG.
    J Med Chem; 2011 Oct 27; 54(20):7030-54. PubMed ID: 21866910
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H.
    Pharmacol Ther; 2008 Feb 27; 117(2):207-31. PubMed ID: 18068807
    [Abstract] [Full Text] [Related]

  • 16. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV, Buccafusco JJ, Wilson C.
    Behav Brain Res; 2008 Dec 16; 195(1):30-8. PubMed ID: 18241938
    [Abstract] [Full Text] [Related]

  • 17. Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity.
    Marcinkowska M, Bucki A, Panek D, Siwek A, Fajkis N, Bednarski M, Zygmunt M, Godyń J, Del Rio Valdivieso A, Kotańska M, Kołaczkowski M, Więckowska A.
    Arch Pharm (Weinheim); 2019 Jul 16; 352(7):e1900041. PubMed ID: 31162703
    [Abstract] [Full Text] [Related]

  • 18. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P, Sohn D, Leideborg R, Caldirola P, Zlatoidsky P, Hanson S, Mohell N, Rosqvist S, Nordvall G, Johansson AM, Johansson R.
    J Med Chem; 2004 Jul 29; 47(16):3927-30. PubMed ID: 15267230
    [Abstract] [Full Text] [Related]

  • 19. Novel M(1) allosteric ligands: a patent review.
    Kuduk SD, Beshore DC.
    Expert Opin Ther Pat; 2012 Dec 29; 22(12):1385-98. PubMed ID: 23092292
    [Abstract] [Full Text] [Related]

  • 20. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A, Anzini M, Vomero S, Canullo L, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Bruni G, Romeo MR, Giorgi G, Donati A.
    J Med Chem; 1999 May 06; 42(9):1556-75. PubMed ID: 10229626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.